Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of tislelizumab vs sorafenib in first-line unresectable hepatocellular carcinoma
jRCT2080224504Phase 3Completed
- Sponsor
- BeiGene
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of tislelizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by BeiGene. Started Jan 2019; status: completed.
02
Drugs
tislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080224504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224504.